Fig. 4
From: Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy
Regulation of bone formation rate by alendronate in ETC-159 treated mice: a Representative fluorescence microscopy images of calcein labeled trabecular bone from treatment groups as indicated. Dynamic histomorphometry of trabecular bone using sagittal sections assessed b mineralizing surface (MS) /bone surface (BS), c mineral apposition rate (MAR) and d bone formation rate (BFR). e Representative fluorescence microscopy images of calcein labeled cortical bone sections from indicated groups. Dynamic histomorphometry of sagittal sections measured f Cortical area fraction (CAF) g cortical width h endocortical-mineralizing perimeter (Ec.M.Pm)/endocortical perimeter (E.Pm), i endocortical mineral apposition rate (Ec.MAR), j endocortical bone formation rate (Ec.BFR), k periosteal mineralizing perimeter (Ps.M.Pm)/periosteal perimeter (Ps.Pm), l periosteal mineral apposition rate (Ps.MAR) and m periosteal bone formation rate (Ps.BFR). n = 5 or 6 mice per group. The data represent the mean ± SD *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
